Nifuroxazide: Polish spelling of Nifuroxazide (intestinal antibiotic for diarrhea)

Nifuroxazide is the spelling used in Poland, Czech Republic, and some other Eastern European countries for the active ingredient Nifuroxazide. Both forms refer to the same molecule, an oral non-absorbable nitrofuran antibiotic. Known brand names are Ercefuryl (France, Poland, Spain) and Antinal (Egypt). Nifuroxazide is not approved in Germany, but is occasionally used in the context of travel or imports.

The classic indication is symptomatic treatment of acute diarrhea, particularly for traveler's diarrhea and uncomplicated bacterial gastroenteritis. The importance of Nifuroxazide has declined in recent years because current guidelines (WHO, IDSA, DGVS) recommend rehydration and symptomatic measures first for acute diarrhea, not antibiotic therapy. In some European countries, Nifuroxazide has even been withdrawn from the market because reliable efficacy data are lacking.

Mechanism of Action

Nifuroxazide belongs to the group of nitrofuran derivatives, similar to furazolidone and nitrofurantoin. The exact mechanism of action is not fully understood; it is suspected to inhibit bacterial dehydrogenases and impair energy metabolism. The substance acts bacteriostatically or bactericidally depending on concentration and pathogen type.

The spectrum of activity includes gram-negative pathogens (E. coli, Salmonella, Shigella, Klebsiella, Enterobacter, Citrobacter) and some gram-positive organisms (Staphylococcus aureus). Pseudomonas aeruginosa, Proteus, and some Bacteroides strains are resistant. It is important that the substance acts in the intestine without being significantly absorbed, which reduces systemic side effects but also excludes effectiveness against systemic infections.

Pharmacokinetically, Nifuroxazide is virtually not absorbed (bioavailability below 5 percent). It remains in the intestinal lumen, acts against pathogenic pathogens, and is excreted with the stool. This pharmacokinetic property makes Nifuroxazide a pure intestinal antibiotic.

Indications

• Acute bacterial diarrhea: in uncomplicated cases without fever and without bloody stools
• Traveler's diarrhea (Turista): as self-medication while traveling, especially in tropical regions
• Enterocolitis: in suspected bacterial pathogens
• Off label: Helicobacter pylori in combination therapy (rare)

Dosage and Administration

Adults and children 6 years and older: 200 mg four times daily (total 800 mg/day) for 5 to 7 days. Children 2 to 6 years: 100 mg three times daily. Infants and toddlers under 2 years: Use in Germany and many other countries is not recommended or contraindicated due to insufficient safety data.

Administration: with or without food. Important is concurrent oral rehydration with electrolyte solutions (WHO solution), since fluid and electrolyte loss during diarrhea is the main cause of complications, not bacterial proliferation.

End of therapy: if diarrhea continues for more than 3 days despite treatment, consult a physician, as other causes (parasites, Clostridioides difficile, viral pathogens) must be ruled out.

Side Effects

Frequent: usually well tolerated. Nausea, abdominal pain, in rare cases worsening of diarrhea.

Occasional: allergic reactions such as rash, pruritus, urticaria. Worsening of glucose 6 phosphate dehydrogenase deficiency with hemolytic anemia.

Rare, but relevant: severe allergic reactions with anaphylaxis and serious skin reactions. For this reason, some European authorities, including the Polish drug authority URPL and EMA pharmacovigilance, have increasingly warned of this risk. In Italy, Belgium, France, and Spain, there have been restrictions or market withdrawals for use in children under 2 years.

Important: in cases of bloody diarrhea, high fever, severe illness, or diarrhea lasting more than 3 days, Nifuroxazide is not sufficient; medical diagnosis with stool culture and possibly systemic antibiotic therapy is required.

Drug Interactions

• Alcohol: theoretical disulfiram-like effect with flushing, nausea, tachycardia; alcohol abstinence during therapy recommended
• Adsorbents (activated charcoal, pectin): reduced efficacy of Nifuroxazide due to binding in the intestinal lumen
• Hormonal contraceptives: theoretical reduction in efficacy due to diarrhea itself, less due to Nifuroxazide; with prolonged diarrhea, additional contraception
• Other antibiotics: do not prescribe concurrently without indication

Special Instructions

Pregnancy and lactation: use should be avoided. Data on safety in pregnancy are limited; alternatives such as pure rehydration or probiotic preparations are usually sufficient for acute diarrhea.

Not for children under 2 years: due to severe allergic reactions, Nifuroxazide has no longer been recommended or is contraindicated in small children in some European countries.

Rehydration as the most important measure: for any acute diarrhea, oral rehydration with electrolyte solutions is the most important treatment. Antibiotic therapy is recommended only for specific indications (severe traveler's diarrhea, confirmed bacterial pathogens).

Traveler's diarrhea prophylaxis: Nifuroxazide is taken as a travel medicine kit item in some countries. However, prophylactic use is not recommended because it promotes resistance development and side effects are unnecessarily incurred.

You might also be interested in

• Nitrofurantoin, related nitrofuran for urinary tract infections
• Loperamide, motility inhibitor for diarrhea
• Saccharomyces boulardii, probiotic therapy
• Azithromycin, standard therapy for severe traveler's diarrhea
• Rifaximin, another non-absorbable intestinal antibiotic

Frequently Asked Questions

Sources

• DGVS guideline acute infectious gastroenteritis
• WHO recommendations for rehydration and diarrhea treatment
• EMA pharmacovigilance reports on Nifuroxazide
• URPL Polish drug authority, Nifuroxazide